Finoriq research workspace
CURIS INC (CRIS) SEC Filings & Filing Highlights
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates. Review CRIS SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
- Company
- CURIS INC (CRIS)
- Ticker
- CRIS
- Market Cap
- $8.7M
- Latest Price
- $4.46
- Industry
- Biotech & Pharma
CURIS INC (CRIS) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for CURIS INC (CRIS).
| Event | Form | Date |
|---|---|---|
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearAmendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K5.03 | 2026-07-02 |
| To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 below i...To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 below is incorporated herein by reference | 8-K3.03 | 2026-07-02 |
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearAmendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K5.03 | 2026-07-01 |
| Broker Non-VotesOn June 25, 2026, Curis, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”) at which the Company’s stockho... | 8-K5.07 | 2026-06-25 |
| 1.The following nominees were elected to the Board as Class III directors for terms of three ye...At the Annual Meeting, the Company’s stockholders voted on five proposals, each of which is described in the Company’s definitive Proxy Sta... | 8-K5.07 | 2026-05-22 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.